^
Contact us  to learn more about
our Premium Content:  News alerts, weekly reports and conference planners
DRUG:

GI-4000

i
Associations
Company:
ImmunityBio
Drug class:
RAS inhibitor
Associations
Phase 2
ImmunityBio, Inc.
Withdrawn
Last update posted :
02/21/2025
Initiation :
09/01/2018
Primary completion :
06/01/2020
Completion :
02/09/2022
HER-2 • ER • PGR
|
HER-2 overexpression • HER-2 amplification
|
5-fluorouracil • Bavencio (avelumab) • albumin-bound paclitaxel • cyclophosphamide • leucovorin calcium • Anktiva (nogapendekin alfa inbakicept-pmln) • ETBX-011 • ETBX-051 • ETBX-061 • GI-4000 • GI-6207 • GI-6301 • NK92-CD16-158V • aldoxorubicin (INNO-206)
Phase 1/2
ImmunityBio, Inc.
Active, not recruiting
Last update posted :
09/27/2023
Initiation :
03/16/2018
Primary completion :
09/01/2023
Completion :
10/01/2023
HER-2 • ER • PGR
|
HER-2 overexpression • HER-2 amplification • PGR expression
|
Avastin (bevacizumab) • cisplatin • 5-fluorouracil • Bavencio (avelumab) • capecitabine • albumin-bound paclitaxel • cyclophosphamide • leucovorin calcium • Anktiva (nogapendekin alfa inbakicept-pmln) • ETBX-011 • ETBX-051 • ETBX-061 • GI-4000 • GI-6207 • GI-6301 • NK92-CD16-158V • aldoxorubicin (INNO-206)
Phase 1
University of Pennsylvania
Withdrawn
Last update posted :
08/17/2016
Initiation :
01/01/2008
Primary completion :
10/01/2009
Completion :
10/01/2009
KRAS
|
KRAS G12C • KRAS G12D • KRAS G12V • KRAS G12 • KRAS Q61L • KRAS expression
|
GI-4000
Phase 2
GlobeImmune
Completed
Last update posted :
04/06/2015
Initiation :
01/01/2006
Primary completion :
02/01/2015
Completion :
02/01/2015
RAS
|
RAS mutation
|
gemcitabine • GI-4000